TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas

References

• Available from http://globocan.iarc.fr/.2013.
   Google Scholar
• Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273–81.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–25.
   PubMed Web of Science ®Google Scholar
• Burcharth F. [Pancreatic cancer 2010]. Ugeskr Laeger 2010;172:1355.
   Google Scholar
• Nakanuma Y, Sato Y. Hilar cholangiocarcinoma is pathologically similar to pancreatic duct adenocarcinoma: suggestions of similar background and development. J Hepatobiliary Pancreat Sci 2014;21:441–7.
   Google Scholar
• Gandou C, Harada K, Sato Y, Igarashi S, Sasaki M, Ikeda H, et al. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules. Hum Pathol 2013;44:811–21.
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722–6.
   PubMed Web of Science ®Google Scholar
• Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 1987;84:5565–9.
   PubMed Web of Science ®Google Scholar
• Sorensen M, Sehested M, Christensen IJ, Larsen JK, Jensen PB. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation. Br J Cancer 1998;77:2152–61.
   Google Scholar
• Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, et al. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer 2009;9:339.
   PubMed Web of Science ®Google Scholar
• Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690–8.
   PubMed Web of Science ®Google Scholar
• Nygard SB, Christensen IJ, Nielsen SL, Nielsen HJ, Brunner N, Spindler KL. Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer. Scand J Gastroenterol 2014;49:84–91.
   PubMed Web of Science ®Google Scholar
• Shen J, Wei J, Wang H, Yue G, Yu L, Yang Y, et al. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer. J Transl Med 2013;11:73.
   Google Scholar
• Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690–8.
   PubMed Web of Science ®Google Scholar
• Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370:143–52.
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306–14.
   PubMed Web of Science ®Google Scholar
• Available from http://www.esmo.org/Guidelines-Practice/Clinical-Practice-Guidelines.2014.
   Google Scholar
• Sanz-Altamira PM, O’Reilly E, Stuart KE, Raeburn L, Steger C, Kemeny NE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 2001;12:501–4.
   PubMed Web of Science ®Google Scholar
• Alberts SR, Fishkin PA, Burgart LJ, Cera PJ, Mahoney MR, Morton RF, et al. CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer 2002;32:107–14.
   PubMedGoogle Scholar
• Karachaliou N, Polyzos A, Kentepozidis N, Kakolyris S, Ziras N, Vardakis N, et al. A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract. Oncology 2010;78:356–60.
   Google Scholar
• Schiffman SC, Metzger T, Dubel G, Andrasina T, Kralj I, Tatum C, et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol 2011;18:431–8.
   Google Scholar
• Chung MJ, Kim YJ, Park JY, Bang S, Song SY, Chung JB, et al. Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer. Chemotherapy 2011;57:236–43.
   Google Scholar
• Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, et al. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol 2013;24:3061–5.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593–600.
   PubMed Web of Science ®Google Scholar
• Eckel F, Brunner T, Jelic S. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22:vi40–4.
   Google Scholar
• Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep 2013;15:182–9.
   PubMed Web of Science ®Google Scholar
• Seufferlein T, Bachet JB, Van CE, Rougier P. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii33–40.
   PubMed Web of Science ®Google Scholar
• Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012;69:1641–5.
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM, Lin EH, Kim GP, Giguere JK, Marshall J, Zalupski M, et al. A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Gastrointest Cancer Res 2012;5:155–60.
   PubMedGoogle Scholar
• Markham C, Stocken DD, Hassan AB. A phase II irinotecan-cisplatin combination in advanced pancreatic cancer. Br J Cancer 2003;89:1860–4.
   Google Scholar
• Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005;23:1228–36.
   PubMed Web of Science ®Google Scholar
• Taieb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 2007;18:498–503.
   PubMed Web of Science ®Google Scholar
• Ueno H, Okusaka T, Funakoshi A, Ishii H, Yamao K, Ishikawa O, et al. A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2007;59:447–54.
   PubMed Web of Science ®Google Scholar
• Neri B, Cipriani G, Grifoni R, Molinara E, Pantaleo P, Rangan S, et al. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer. Oncol Res 2009;17:559–64.
   PubMed Web of Science ®Google Scholar
• Ulrich-Pur H, Raderer M, Verena KG, Schull B, Schmid K, Haider K, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003;88:1180–4.
   PubMed Web of Science ®Google Scholar
• Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001;6:488–95.
   PubMed Web of Science ®Google Scholar
• Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009;101:1658–63.
   PubMed Web of Science ®Google Scholar
• Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 2009;63:1141–5.
   PubMed Web of Science ®Google Scholar
• Oh SY, Kim HJ, Kim TH, Lee GW, Kim HG, Jeong CY, et al. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Invest New Drugs 2010;28:343–9.
   Google Scholar
• Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004;67:93–7.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Rigatos SK, Dimopoulos MA, Giannakakis T, Foutzilas G, Kouroussis C, et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2003;14:388–94.
   PubMed Web of Science ®Google Scholar
• Nygard SB, Christensen IJ, Nielsen SL, Nielsen HJ, Brunner N, Spindler KL. Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer. Scand J Gastroenterol 2014;49:84–91.
   PubMed Web of Science ®Google Scholar
• Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? Br J Cancer 2014;110:2178–86.
   PubMed Web of Science ®Google Scholar
• cBioportal cancer genomics. Available from http://www.cbioportal.org/.2014.
   Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:l1.
   Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401–4.
   PubMed Web of Science ®Google Scholar
• Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014;311:392–404.
   PubMed Web of Science ®Google Scholar
• Stanley R, Hamilton, Lauri A, editors. WHO: pathology and genetics of tumours of the digestive system -who classification of tumours. IARC; Lyon France: 2000.
   Google Scholar
• Romer MU, Nygard SB, Christensen IJ, Nielsen SL, Nielsen KV, Muller S, et al. Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Mol Oncol 2013;7:101–11.
   Google Scholar
• Romer MU, Jensen NF, Nielsen SL, Muller S, Nielsen KV, Nielsen HJ, et al. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand J Gastroenterol 2012;47:68–79.
   PubMed Web of Science ®Google Scholar
• Smith DH, Christensen IJ, Jensen NF, Markussen B, Romer MU, Nygard SB, et al. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort. PLoS One 2013;8:e60613.
   Web of Science ®Google Scholar
• Stenvang J, Smid M, Elsen SL. Topoisomerase I gene copy number aberration is a frequent finding in clinical breast cancer samples [abstract]. Conference: 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium; 04 – 08 December 2012; San Antonio, TX United States.
   Google Scholar
• Hansen JB, Nygard SB, Nielsen SL, Brunner N, Bjartell A, Vainer B, et al. TOP1 gene copy number analysis as a predictive biomarker to select prostate cancer patients for irinotecan treatment. Unpublished 2014.
   Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067–72.
   PubMed Web of Science ®Google Scholar
• Stenvang J, Kumler I, Nygard SB, Smith DH, Nielsen D, Brunner N, et al. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol 2013;3:313.
   PubMedGoogle Scholar
• De Angelis PM, Clausen OP, Schjolberg A, Stokke T. Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes. Br J Cancer 1999;80:526–35.
   PubMed Web of Science ®Google Scholar
• De Angelis PM, Stokke T, Beigi M, Mjaland O, Clausen OP. Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer. Int J Colorectal Dis 2001;16:38–45.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997–4013.
   PubMed Web of Science ®Google Scholar
• Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 2013;109:920–5.
   PubMed Web of Science ®Google Scholar
• Von Hoff A, Li CP, Wang-GIllian A, et al. NAPOLI-1: randomized fase III study of MM-398 (NAL-IRI) with or without 5-flourouracil and leucovorin in metastatic pancreatic cancer progressed on gemcitabine based therapy [abstract]. Ann Oncol 2014;25:ii105.
   Google Scholar